JGC
TARS icon

J. Goldman & Co’s Tarsus Pharmaceuticals TARS Stock Holding History

J. Goldman & Co’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,100
Closed -$393K – 629
2024
Q4 		$393K Sell
7,100
-87,400
-92% -$3.97M 0.01% 379
2024
Q3 		$3.11M Buy
+94,500
New +$2.66M 0.09% 205

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

J. Goldman & Co's TARS Position: Q2 2026 in Review

J. Goldman & Co increased its Tarsus Pharmaceuticals (TARS) stake by 84% in Q2 2026, buying an estimated $783K and bringing the position to 26,800 shares worth $1.69M. The position accounts for 0.04% of the portfolio, ranked #374.

J. Goldman & Co first reported a position in TARS in Q2 2021 and has held it in 20 quarters since. The position peaked at $18.3M in Q3 2024. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • J. Goldman & Co held 26,800 shares of Tarsus Pharmaceuticals worth $1.69M as of Q2 2026.
  • J. Goldman & Co bought 12,259 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $783K.
  • Tarsus Pharmaceuticals made up 0.04% of J. Goldman & Co's portfolio in Q2 2026, its #374 holding.
  • J. Goldman & Co first reported a position in Tarsus Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • J. Goldman & Co's Tarsus Pharmaceuticals position peaked at $18.3M in Q3 2024.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.